Efficacy and safety of trastuzumab biosimilar in HER2+ve metastatic breast cancer: A multicenter phase III study

被引：1
|
作者：
Mohan, K. [1 ]
Prajapati, A. [2 ]
Kothari, R. K. [3 ]
Mondal, S. [4 ]
Nagarkar, R. [5 ]
Kane, S. B. [6 ]
Santa, A. [1 ]
Dadke, D. [7 ]
机构：
[1] Basavatarakam Indo Amer Canc Hosp & Res Inst, Med Oncol, Hyderabad, India
[2] Curateq Biol Private Ltd, Clin Dev, Hyderabad, India
[3] Narayana Multispecialty Hosp, Med Oncol, Ahmadabad, Gujarat, India
[4] Nilratan Sircar Med Coll & Hosp, Radiotherapy, Kolkata, India
[5] HCG Manavata Canc Ctr, Surg Oncol, Nasik, India
[6] RST Reg Canc Ctr, Med Oncol, Nagpur, Maharashtra, India
[7] Curateq Biol Private Ltd, Hyderabad, India
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.201
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
67P
引用
收藏
页码：S1491 / S1491
页数：1
相关论文
共 50 条
  • [1] Efficacy and Safety of BP02 (Trastuzumab Biosimilar) in HER2-Positive Metastatic Breast Cancer: A Multicenter Phase III Study
    Mohan, M. V. T. Krishna
    Prajapati, Arpitkumar
    Kothari, Rushabh
    Mandal, Srikrishna
    Srikanth, Ranganatha Rao
    Nagarkar, Rajnish
    Khane, Shriram
    Santa, Ayyagari
    Dadke, Disha
    CLINICAL DRUG INVESTIGATION, 2024, 44 (07) : 513 - 525
  • [2] Efficacy, safety and pharmacokinetics of a proposed trastuzumab biosimilar HLX02 compared with trastuzumab in metastatic breast cancer: A global phase III study
    Zhang, Q.
    Xu, B.
    Sun, T.
    Li, W.
    Teng, Y.
    Hu, X.
    Bondarenko, I.
    Adamchuk, H.
    Li, Y.
    Shan, B.
    Liu, S.
    Jiang, W.
    Zhang, X.
    Luk, A.
    Chai, K.
    ANNALS OF ONCOLOGY, 2020, 31 : S356 - S356
  • [3] A comparative phase III clinical study to evaluate efficacy and safety of TrastuRel™ (biosimilar trastuzumab) and innovator trastuzumab in patients with metastatic human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer
    Apsangikar, Prasad
    Chaudhry, Sunil
    Naik, Manoj
    Deoghare, Shashank
    Joseph, Jamila
    INDIAN JOURNAL OF CANCER, 2017, 54 (04) : 664 - 668
  • [4] Efficacy and safety of first China-manufactured trastuzumab biosimilar HLX02 for metastatic breast cancer: A phase III trial
    Xu, B.
    Zhang, Q.
    Sun, T.
    Li, W.
    Teng, Y.
    Hu, X.
    Bondarenko, I.
    Adamchuk, H.
    Zhang, L.
    Trukhin, D.
    Li, B.
    Shan, B.
    Cheng, J.
    Peng, T.
    Jiang, W.
    Liu, S.
    Zhang, X.
    Wang, Q.
    Liu, E.
    Luk, A. Y.
    ANNALS OF ONCOLOGY, 2019, 30 : 106 - +
  • [5] Safety and Efficacy of Trastuzumab Deruxtecan for Metastatic HER2+and HER2-low Breast Cancer
    Qureshi, Zaheer
    Altaf, Faryal
    Jamil, Abdur
    Siddique, Rimsha
    Fatima, Eeshal
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2024, 47 (11): : 535 - 541
  • [6] Updated results of a randomized phase III study of trastuzumab, paclitaxel and carboplatin versus trastuzumab and paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC): efficacy and safety
    Robert, Nicholas
    Leyland-Jones, Brian
    Asmar, Lina
    Belt, Robert
    Ilegbodu, Des
    Loesch, David
    Raju, Robert
    Cobleigh, Melody
    Albain, Kathy
    Slamon, Dennis
    ANNALS OF ONCOLOGY, 2004, 15 : 39 - 39
  • [7] Multicenter phase I/II study of efficacy, safety, and pharmacokinetics of vinorelbine and trastuzumab as first-line therapy for HER2-overexpressing metastatic breast cancer
    Aogi, Kenjiro
    Toi, Masakazu
    Iwata, Hiroji
    Ito, Yoshinori
    Sano, Muneaki
    Sato, Yasuyuki
    Saeki, Toshiaki
    Takashima, Shigemitsu
    ANNALS OF ONCOLOGY, 2006, 17 : 75 - 76
  • [8] Efficacy and safety of biosimilar ABP 980 compared with trastuzumab in HER2 positive early breast cancer
    von Minckwitz, G.
    Ponomarova, O.
    Morales, S.
    Zhang, N.
    Hanes, V.
    ANNALS OF ONCOLOGY, 2017, 28
  • [9] Weekly docetaxel and trastuzumab for her-2-overexpressing metastatic breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study
    Takao, S.
    Kohno, N.
    Miyashita, M.
    Kokufu, I.
    Wakita, K.
    EJC SUPPLEMENTS, 2004, 2 (03): : 137 - 138
  • [10] Safety and efficacy of eribulin and trastuzumab in anti-HER2 therapy pretreated patients with HER2-positive metastatic breast cancer: A Japanese multicenter phase 2 study (SBP-04 study)
    Shien, T.
    Ikeda, M.
    Ohtani, S.
    Hara, F.
    Takahashi, M.
    Tuji, H.
    Yoshitomi, S.
    Matsuoka, K.
    Ogasawara, Y.
    Taira, N.
    Doihara, H.
    Ohsumi, S.
    ANNALS OF ONCOLOGY, 2016, 27
12345